• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500 Rises 1%; US Wholesale Inventories Fall In August

    10/10/23 12:04:06 PM ET
    $AKRO
    $ATHX
    $INTZ
    $SMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday.

    The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also rose, gaining, 1.10% to 4,383.17.

    Check This Out: Walgreens Likely To Report Lower Q4 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Consumer discretionary shares rose by 1.4% on Tuesday.

    In trading on Tuesday, energy shares fell by around 0.1%.

     

    Top Headline

     

    U.S. wholesale inventories fell 0.1% month-over-month in August.

     

    Equities Trading UP

     

    SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares shot up 99% to $3.3841 after the company announced it secured a majority stake in True Gold Consortium.

    Shares of Intrusion Inc. (NASDAQ:INTZ) got a boost, shooting 46% to $0.5094. Intrusion has been awarded a $5 million agreement with a large telecommunications provider to provide Intrusion Shield support for its data centers.

    Startek, Inc. (NYSE:SRT) shares were also up, gaining 29% to $4.2191 as the company agreed to be acquired by funds managed by CSP Management Limited for $4.30 per share in cash.

     

    Equities Trading DOWN

     

    Akero Therapeutics, Inc. (NASDAQ:AKRO) shares dropped 66% to $16.72 after the company reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin.

    Shares of Athersys, Inc. (NASDAQ:ATHX) were down 47% to $0.16 after the company reported interim analysis results of MASTERS-2 clinical study with multistem in ischemic stroke and signed a Memorandum of Understanding for global ARDS license with Healios.

    Ventyx Biosciences, Inc. (NASDAQ:VTYX) was down, falling 24% to $22.95 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.

    Also Check This Out: Check Out 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street's Most Accurate Analysts

     

    Commodities

     

    In commodity news, oil traded down 1% to $85.53 while gold traded up 0.3% at $1,869.50.

    Silver traded up 0.2% to $21.96 on Tuesday while copper fell 0.9% to $3.6145.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 1.8% London’s FTSE 100 gained 1.74% while Spain’s IBEX 35 Index rose 2.3% The German DAX rose 1.86% French CAC 40 climbed 1.84%, while Italy’s FTSE MIB Index gained 2.3%.

    Industrial production in Italy rose 0.2% month-over-month in August following a revised 0.9% fall in July. Retail sales in the UK rose 2.8% from a year ago in September.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Tuesday, with Japan’s Nikkei 225 gaining 2.43%, China’s Shanghai Composite Index falling 0.70% and Hong Kong’s Hang Seng Index gaining 0.84%. India’s S&P BSE Sensex, meanwhile, rose 0.9%.

    Japan's current account surplus narrowed to JPY 2.280 trillion in August from JPY 2.772 trillion in the prior month, compared to market estimates of JPY 3.091 trillion.

     

    Economics

     

    The NFIB Small Business Optimism Index fell for a second month to a reading of 90.8 in September from 91.3 in the prior month.

    U.S. wholesale inventories fell 0.1% month-over-month in August.

    Now Read This: Top 3 Tech And Telecom Stocks You May Want To Dump In October

    Get the next $AKRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKRO
    $ATHX
    $INTZ
    $SMX

    CompanyDatePrice TargetRatingAnalyst
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Akero Therapeutics Inc.
    $AKRO
    9/4/2025$72.00Buy
    H.C. Wainwright
    Akero Therapeutics Inc.
    $AKRO
    8/4/2025$76.00Buy
    TD Cowen
    Akero Therapeutics Inc.
    $AKRO
    1/30/2025$35.00 → $63.00Neutral → Buy
    BofA Securities
    Akero Therapeutics Inc.
    $AKRO
    1/27/2025$50.00 → $72.00Buy
    H.C. Wainwright
    Akero Therapeutics Inc.
    $AKRO
    11/18/2024$65.00Buy
    Citigroup
    Akero Therapeutics Inc.
    $AKRO
    4/22/2024$30.00Neutral
    BofA Securities
    Ventyx Biosciences Inc.
    $VTYX
    3/12/2024$12.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $AKRO
    $ATHX
    $INTZ
    $SMX
    SEC Filings

    View All

    SEC Form 6-K filed by SMX (Security Matters) Public Limited Company

    6-K - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    2/12/26 9:32:03 AM ET
    $SMX
    Industrial Machinery/Components
    Technology

    SEC Form 424B3 filed by SMX (Security Matters) Public Limited Company

    424B3 - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    2/9/26 6:03:49 AM ET
    $SMX
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/6/26 4:13:53 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

    Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (NASDAQ:VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation acr

    1/7/26 4:17:00 PM ET
    $LLY
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk has completed its acquisition of Akero Therapeutics

    Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. ("Akero") (NASDAQ:AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right ("CVR"). Each CVR entitles its holder to an additional payment of 6 USD per share in cash (or aggregated value of 0.5 billion USD) upon US regulatory approval of Akero's lead candidate EFX for the tr

    12/9/25 8:51:19 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Architectural Transformation, Not Add-Ons

    DENVER, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cemtrex (NASDAQ:CETX) and Xeriant (OTCQB:XERI) announced major strategic developments that echo a broader shift taking place across advanced technology markets, like SMX (NASDAQ:SMX), whose recent revaluation demonstrated what happens when investors recognize that a company is not merely selling products, but reshaping the underlying architecture of an industry. Cemtrex and Xeriant are moving beyond conventional category labels. They are building the core infrastructure that allows entire sectors to function differently. But each is doing so with its own distinct strategic lens: Cemtrex through mission-critical aerospace and defense engineering, a

    12/8/25 9:49:16 AM ET
    $CETX
    $SMX
    Electrical Products
    Technology
    Industrial Machinery/Components

    $AKRO
    $ATHX
    $INTZ
    $SMX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 13, 2021 - FDA In Brief: FDA Releases Investigation Report Following 2020 Salmonella Outbreak Linked to Red Onions

    For Immediate Release: May 13, 2021 The following quote is attributed to Frank Yiannas, FDA Deputy Commissioner for Food Policy and Response “The FDA has been working with the CDC, state partners and Canadian officials to investigate the largest Salmonella Newport outbreak in over a decade, which was linked to red onions. The FDA, today, released a 2020 Salmonella Outbreak Linked to Red Onions Report that includes an o

    5/13/21 3:17:14 PM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Akero Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akero Therapeutics with a rating of Buy and set a new price target of $72.00

    9/4/25 8:59:48 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Akero Therapeutics with a new price target

    TD Cowen initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $76.00

    8/4/25 8:20:06 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Head T Joe covered exercise/tax liability with 11,085 shares, decreasing direct ownership by 13% to 72,556 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/26/26 5:31:55 PM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Chief Financial Officer Pinson Kimberly covered exercise/tax liability with 11,085 shares, decreasing direct ownership by 18% to 50,069 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/26/26 5:31:29 PM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Chief Executive Officer Scott Anthony bought $2,126 worth of shares (2,175 units at $0.98), increasing direct ownership by 0.34% to 638,793 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:57:35 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Scott Anthony bought $2,126 worth of shares (2,175 units at $0.98), increasing direct ownership by 0.34% to 638,793 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:57:35 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Chief Financial Officer Pinson Kimberly bought $2,444 worth of shares (2,500 units at $0.98), increasing direct ownership by 4% to 61,154 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:58:01 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Chief Executive Officer Scott Anthony bought $2,124 worth of shares (1,091 units at $1.95), increasing direct ownership by 0.17% to 654,872 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    7/2/25 8:44:40 PM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Leadership Updates

    Live Leadership Updates

    View All

    Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

    Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD

    4/1/25 7:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pitney Bowes Appoints Lance Rosenzweig as Permanent CEO and Strengthens Board of Directors

    Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or the "Company"), a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of Lance Rosenzweig as the Company's permanent Chief Executive Officer ("CEO"), effective immediately. The Company's Board of Directors (the "Board") carried out an extensive CEO search process that was supported by a nationally recognized executive recruiting firm and included both internal and external candidates. After assessing Mr. Rosenzweig's considerable contributions as interim CEO and his track record of value creation at Pitney Bowes and at other co

    10/29/24 8:00:00 AM ET
    $GM
    $GME
    $IAC
    Auto Manufacturing
    Industrials
    Electronics Distribution
    Consumer Discretionary

    Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

    -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second

    8/9/24 7:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Financials

    Live finance-specific insights

    View All

    Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

    VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this studyVentyx to hold conference call and webcast 4:30pm ET on Wednesday, October 22nd SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences,

    10/22/25 4:02:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

    Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious me

    1/27/25 6:30:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

    Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). Conferenc

    1/24/25 4:05:00 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $INTZ
    $SMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 3:59:41 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 3:06:49 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care